Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia.

Cancer reports (Hoboken, N.J.) - 1 Mar 2023

Yunis Luz K, Linares-Ballesteros Adriana, Aponte Nelson, Barros Gisela, García Johnny, Niño Laura, Uribe Gloria, Quintero Edna, Yunis Juan J

Abstract excerpt

BACKGROUND AND AIM: Different studies have shown pharmacogenetic variants related to drug toxicity in acute myeloid leukemia (AML) patients. Our aim was to identify the association between ABCB1, CDA, DCK, GSTT1, and GSTM1 variants with clinical outcomes and toxicity in pediatric patients with AML. METHODS: Fifty-one confirmed de novo AML pediatric patients were included. A SNaPshot™ assay and conventional PCR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colombia

Share to Genotype

Share to Leukemia, Myeloid, Acute

Share to Pharmacogenetics

Source

Open in PubMed Open full text

Identifiers

PMID: 36316809
DOI: 10.1002/cnr2.1744
PMCID: PMC10026301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia.PMID 36316809Read ↗

Pharmacogenomics and the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.Semantic proximity Read ↗

Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

ABCB1 Polymorphisms and Childhood Acute Lymphoblastic Leukemia Risk: A Meta-Analysis.Semantic proximity Read ↗

CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility.Semantic proximity Read ↗

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.Semantic proximity Read ↗

Pharmacogenetic aspects of efficacy and safety of methotrexate treatment in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Association of ABCB1, ABCC5 and xanthine oxidase genetic polymorphisms with methotrexate adverse reactions in Mexican pediatric patients with ALL.Semantic proximity Read ↗

Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.Semantic proximity Read ↗

Evaluation of Methotrexate Toxicity and its Association with ABCB1 Genetic Polymorphism in Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias.Semantic proximity Read ↗

The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.